Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Key Points Interested in Tarsus Pharmaceuticals, Inc.? Here are five stocks we like better. Tarsus Pharmaceuticals closed its acquisition of iRenix Medical, adding IRX-101 to its pipeline and giving the company its first strategic position in the retina market.

The deal expands Tarsus beyond its core eye-care focus. IRX-101 is designed to replace povidone-iodine for patients receiving repeated intravitreal injections, aiming to reduce pain, irritation and ocular surface damage. In a Phase IIb/III study, it showed statistically significant improvements versus povidone-iodine, including less pain and less corneal staining.

Tarsus plans to start a pivotal Phase III COMFORT study in the first half of 2027, with top-line data expected in 2028. The acquisition cost was about $75 million upfront, with up to $490 million in milestones and royalties possible if the drug succeeds. 3 Biotech Catalysts Present Major Opportunity Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc.

, adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market. On an investor call discussing the deal, Bobby Azamian, Tarsus' chief executive officer and chairman, said the acquisition represents "the next step in expanding our pipeline" and establishes the company's first strategic position in retina. He said IRX-101 is aimed at improving the experience for patients who undergo repeated intravitreal injections, which are commonly used in retinal disease treatment.

→ Scotiabank Sees a New Growth Story for Cloudflare Tarsus executives said more than 11 million intravitreal injections are performed annually in the United States, with many patients returning every four to eight weeks for years to preserve their vision. The company said antiseptic preparation before those injections has seen little meaningful innovation in more than 40 years. IRX-101 Targets Pain and Ocular Surface Damage Liz Yoo, Tarsus' chief medical officer, said IRX-101 is intended to address shortcomings associated with povidone-iodine, the long-used antiseptic preparation for intravitreal injections.

Yoo said retinal specialists frequently hear complaints from patients about burning, irritation and pain after antiseptic preparation, and Tarsus survey results showed more than three-quarters of retinal specialists attributed patient complaints to povidone-iodine rather than the injection needle. Story Continues → PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Yoo said povidone-iodine can cause ocular surface damage and corneal epithelial cell death, potentially leading to days of pain and irritation. She said that burden can make some patients more reluctant to continue ongoing treatment.

According to Tarsus, IRX-101 is a chlorine dioxide solution designed to target the bacterial cell wall. Yoo said that differs from povidone-iodine, which she characterized as nonspecific and broadly toxic. → A Market Panic Just Discounted the AI Highway's Tollbooth In the iRenix RELIEF Phase II-B/III trial, IRX-101 was compared directly with povidone-iodine in patients undergoing intravitreal injections.

Yoo said IRX-101 showed statistically significant improvements in post-procedural pain and corneal fluorescein staining, a test used to assess ocular surface damage. She added that approximately half of patients treated with IRX-101 reported a pain score of zero one hour after the procedure. Phase III Study Planned for 2027 Tarsus said it expects to begin a pivotal Phase III study of IRX-101 in the first half of 2027, with top-line data expected in 2028.

Yoo said the study, named COMFORT, is expected to enroll approximately 270 patients and compare IRX-101 directly against povidone-iodine. During the question-and-answer portion of the call, Yoo said the Phase III trial is a pivotal safety study that will also explore endpoints that could support the label, including findings related to pain and staining. Azamian clarified that the FDA will also require an in vitro antimicrobial efficacy study to obtain an antisepsis label, and that Tarsus plans to run the studies in parallel.

Jeff Farrow, Tarsus' chief financial officer and chief strategy officer, said the company expects the cost to approval to be approximately $20 million to $30 million. He also said IRX-101 is supported by patent protection expected into at least 2039. Deal Terms Include Cash, Stock and Milestones Under the acquisition agreement, Tarsus will pay upfront consideration of approximately $75 million, consisting of $37.

5 million in cash and $37.5 million in Tarsus common stock. The agreement also includes potential approval and commercial milestones of up to $490 million, along with low- to mid-single-digit tiered royalties upon achievement of certain milestones.

Farrow said the acquisition has closed and was financed with the company's balance sheet. He said the